MX2009004196A - Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes. - Google Patents

Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes.

Info

Publication number
MX2009004196A
MX2009004196A MX2009004196A MX2009004196A MX2009004196A MX 2009004196 A MX2009004196 A MX 2009004196A MX 2009004196 A MX2009004196 A MX 2009004196A MX 2009004196 A MX2009004196 A MX 2009004196A MX 2009004196 A MX2009004196 A MX 2009004196A
Authority
MX
Mexico
Prior art keywords
medicament
prevention
preparation
treatment
autoimmune diseases
Prior art date
Application number
MX2009004196A
Other languages
English (en)
Spanish (es)
Inventor
Enrico Garaci
Luigina Romani
Francesco Bistoni
Guido Rasi
Paola Sinibaldi Vallebona
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MX2009004196A publication Critical patent/MX2009004196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2009004196A 2006-10-27 2007-09-27 Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes. MX2009004196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000584A ITRM20060584A1 (it) 2006-10-27 2006-10-27 Uso della timosina alfa 1 la preparazione di un medicamento per la prevenzione e la cura delle malattie autoimmuni
PCT/IT2007/000677 WO2008050363A2 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
MX2009004196A true MX2009004196A (es) 2009-06-30

Family

ID=39322489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004196A MX2009004196A (es) 2006-10-27 2007-09-27 Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes.

Country Status (13)

Country Link
US (1) US20100004174A1 (cg-RX-API-DMAC7.html)
EP (1) EP2086569A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010507650A (cg-RX-API-DMAC7.html)
KR (1) KR20090096688A (cg-RX-API-DMAC7.html)
CN (1) CN101534853A (cg-RX-API-DMAC7.html)
AU (1) AU2007310416A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718010A2 (cg-RX-API-DMAC7.html)
CA (1) CA2666609A1 (cg-RX-API-DMAC7.html)
EA (1) EA200900602A1 (cg-RX-API-DMAC7.html)
IL (1) IL198291A0 (cg-RX-API-DMAC7.html)
IT (1) ITRM20060584A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009004196A (cg-RX-API-DMAC7.html)
WO (1) WO2008050363A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100248272A1 (en) * 2009-03-31 2010-09-30 Cornell University Method for identifying Smk box riboswitch modulating compounds
WO2025078961A1 (en) * 2023-10-13 2025-04-17 Gufic Biosciences Limited Composition and method for treatment of endometriosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
CN1198950A (zh) * 1998-04-24 1998-11-18 崔泊 一种结肠炎新药的制备
CN1628796A (zh) * 2004-08-20 2005-06-22 康合堂 一种治疗溃疡性结肠炎的药物

Also Published As

Publication number Publication date
EP2086569A2 (en) 2009-08-12
WO2008050363A2 (en) 2008-05-02
JP2010507650A (ja) 2010-03-11
BRPI0718010A2 (pt) 2013-11-19
US20100004174A1 (en) 2010-01-07
WO2008050363A3 (en) 2008-06-26
ITRM20060584A1 (it) 2008-04-28
CN101534853A (zh) 2009-09-16
KR20090096688A (ko) 2009-09-14
IL198291A0 (en) 2011-08-01
WO2008050363A8 (en) 2009-06-04
EA200900602A1 (ru) 2009-10-30
AU2007310416A1 (en) 2008-05-02
CA2666609A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
IL249165A0 (en) Use of an antigen-mhc complex to prepare drugs for the prevention and treatment of autoimmune conditions
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
EP1874334A4 (en) COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
PL1656372T3 (pl) Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
AU4063601A (en) Use of il-18 inhibitors
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MY147247A (en) Organic compounds and their uses
IL204990A0 (en) Use of 3,11 b-cis - dihydrotetrabenazine in the treatment of multiple sclerosis and autoimmune myelitis
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
TN2009000135A1 (en) Use of modified cyclosporins
WO2008050363A8 (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases
WO2008022807A3 (en) Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
WO2009033814A3 (en) Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
JP2010507650A5 (cg-RX-API-DMAC7.html)
MX2009004237A (es) Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de alergias.
WO2010150082A3 (en) Use of chromogranin a and peptidic derivatives thereof in the treatment of inflammation
EP1819724A4 (en) BETA 2-GLYCOPROTEIN I COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
WO2009033809A3 (en) Use of a peptide as a therapeutic agent
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal